N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.
about
alpha v beta3 and alpha5beta1 integrin recycling pathways dictate downstream Rho kinase signaling to regulate persistent cell migration.Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathwayNoninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGDGuidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer CellsAnti-angiogenic alternatives to VEGF blockadeGetting in shape: controlling peptide bioactivity and bioavailability using conformational constraintsCharacterization and NMR solution structure of a novel cyclic pentapeptide inhibitor of pathogenic hantavirusesIntroducing lasso peptides as molecular scaffolds for drug design: engineering of an integrin antagonistAtomic Basis for the Species-specific Inhibition of V Integrins by Monoclonal Antibody 17E6 Is Revealed by the Crystal Structure of V 3 Ectodomain-17E6 Fab ComplexThe cyclic cystine ladder of theta-defensins as a stable, bifunctional scaffold: A proof-of-concept study using the integrin-binding RGD motifFOSL1 controls the assembly of endothelial cells into capillary tubes by direct repression of αv and β3 integrin transcriptionThe integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cellsRGDechi-hCit: αvβ3 selective pro-apoptotic peptide as potential carrier for drug delivery into melanoma metastatic cellsVicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activitiesEvaluation of the anti-angiogenic properties of the new selective αVβ3 integrin antagonist RGDechiHCitIntegrins in cancer: biological implications and therapeutic opportunitiesDesign, synthesis and structure-activity relationship study of wollamide B; a new potential anti TB agent.Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imagingPreclinical molecular imaging of tumor angiogenesis.Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments.The thioesterase domain from a nonribosomal peptide synthetase as a cyclization catalyst for integrin binding peptides.Investigation of the interaction between the atypical agonist c[YpwFG] and MOR.Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression.Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumorsStructure-activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptidesA gene expression classifier of node-positive colorectal cancerRecent trends in targeted anticancer prodrug and conjugate design.Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography.Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies.The use of one-bead one-compound combinatorial library technology to discover high-affinity αvβ3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handleN-terminal and C-terminal heparin-binding domain polypeptides derived from fibronectin reduce adhesion and invasion of liver cancer cells.The effect of superparamagnetic iron oxide with iRGD peptide on the labeling of pancreatic cancer cells in vitro: a preliminary study.Synthesis of chemically modified bioactive peptides: recent advances, challenges and developments for medicinal chemistry.Toward the development of podocyte-specific drugs.Mesenchymal migration as a therapeutic target in glioblastoma.On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds.Increasing αvβ3 selectivity of the anti-angiogenic drug cilengitide by N-methylation.Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancerIdentification of the alphavbeta3 integrin-interacting motif of betaig-h3 and its anti-angiogenic effect.Evaluation of multivalent, functional polymeric nanoparticles for imaging applications.
P2860
Q24305037-0BA6FBA6-94ED-485A-AF36-F7A7DB826FE5Q24647759-0D81DC9F-0666-4B30-8BFD-00804EF00BC5Q24805375-0558DF3B-E037-42E4-B763-355998519DD8Q26738643-70BBA3DC-8A87-4774-9424-FCD703612E0CQ26775947-2692C381-8352-40DA-A11C-4F1829388F32Q27021652-C73E269D-189F-43A2-A5A7-E59DC856D956Q27644491-AD679F7F-A575-4BAB-A2F3-51B3D9BF5C42Q27671423-DA98808E-4280-43D2-AC27-F69815488479Q27682746-BE1C3688-BB8F-4358-A9EA-CCE818032F30Q27688055-1FEB9FC1-71A1-42AF-AF69-C351F93948EAQ28283351-1BF5670A-C06D-4E01-9F2F-B69456E7B681Q28474747-98C49AD7-9DB9-475A-AB82-56DC65140F97Q28543148-564066B4-6919-4150-8CBA-C12E6F157FEEQ28751757-91AF2B2C-87DB-489A-993B-46DB1D41025DQ29395541-076A19F8-9940-4E9A-B5CE-05F231A2808FQ29614536-68309AB1-1369-4156-9010-4345C9924212Q30313238-7282087B-4B9D-4565-BF7E-D3A928A67421Q30395463-57A5496D-C9AA-42CB-A4A9-84255CC80FF3Q30475818-20804860-BB09-497A-BEF3-A8A1F8248CAFQ30483866-B143F0FF-5FDD-47D4-975A-AC1258A5EC43Q31035902-37268872-7770-4A0F-A379-4ED2DA729A6DQ31151838-FA232056-F993-4FA4-8E3C-C1CAD29E030CQ33215681-E453D4E9-F0BA-43B5-9129-5340DAB698B5Q33237917-6481FD6B-F63E-44A6-B7A9-5DA6108A65FDQ33355086-977B9E35-1A72-4E0C-A828-858EA8D9BEFDQ33507915-BDA35F78-052C-4E80-A87C-64A6CE8D6A2FQ33573762-71382AD1-720D-49C3-9BC4-3956A2D7E381Q33574585-C3610332-28AA-4D75-8AD7-8191DE7D850AQ33585575-2EC898FC-1633-4437-9A2D-A3D366423BBAQ33698802-E1705772-F023-4272-BE8A-B7F78CA44E34Q33715856-42116507-E659-44C1-B45B-40588DC58AEDQ33746572-2A18C94B-B577-4347-A834-F35B18026229Q33852418-E3A784CE-C75E-4802-8CAF-00A458EBCA56Q33872286-5C0C20DA-FAAC-484B-8DF7-D482B0BBBDE7Q34002994-3839B62C-49F6-4E51-827E-09F64BD5F091Q34030237-877BD514-7A10-49CA-8C24-C37272C8FAADQ34030885-D42FF016-7FC6-47A3-9050-9145595B981FQ34128953-619FE391-8048-4BA9-83FA-C152B950C50EQ34191650-38539B80-D42F-4EAE-8F24-C7F9E3CBE068Q34594347-92C14EAF-0441-4270-8F33-614DFF49AA0B
P2860
N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
N-Methylated cyclic RGD peptid ...... )beta(3) integrin antagonists.
@ast
N-Methylated cyclic RGD peptid ...... )beta(3) integrin antagonists.
@en
type
label
N-Methylated cyclic RGD peptid ...... )beta(3) integrin antagonists.
@ast
N-Methylated cyclic RGD peptid ...... )beta(3) integrin antagonists.
@en
prefLabel
N-Methylated cyclic RGD peptid ...... )beta(3) integrin antagonists.
@ast
N-Methylated cyclic RGD peptid ...... )beta(3) integrin antagonists.
@en
P2093
P356
P1476
N-Methylated cyclic RGD peptid ...... )beta(3) integrin antagonists.
@en
P2093
Dechantsreiter MA
Goodman SL
Hölzemann G
P304
P356
10.1021/JM970832G
P407
P577
1999-08-01T00:00:00Z